|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's range||40.81 - 42.08|
|52-week range||20.87 - 69.58|
|Beta (5Y monthly)||3.16|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||63.13|
Surgery Partners (SGRY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bain Capital Private Equity's Managing Director Devin O'Reilly explains why his firm sought out its new investment in PartSource and other investment areas Bain likes in the healthcare space.
Image source: The Motley Fool. Surgery Partners, inc (NASDAQ: SGRY)Q2 2021 Earnings CallAug 4, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to Surgery Partners, Inc.